<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787618</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-006</org_study_id>
    <nct_id>NCT00787618</nct_id>
  </id_info>
  <brief_title>Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females</brief_title>
  <official_title>A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PK and safety profile of Proellex® in females with various stages of impaired renal function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the pharmacokinetics and safety profile of Proellex® in females with
      various stages of impaired renal function and in volunteers with normal renal function
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Increased LFTs
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Proellex</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>50 mg Proellex Mild impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg Proellex single dose Female subjects with mild renal impairment function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Proellex Moderate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg Proellex, Female subjects with moderate renal impairment function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Proellex, Normal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg Proellex, Female subjects with normal renal function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg Proellex</intervention_name>
    <description>Single dose</description>
    <arm_group_label>50 mg Proellex Mild impairment</arm_group_label>
    <arm_group_label>50 mg Proellex Moderate</arm_group_label>
    <arm_group_label>50 mg Proellex, Normal</arm_group_label>
    <other_name>Telapristone acetate</other_name>
    <other_name>Proellex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Speak, read, and understand English or Spanish and is willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures;

          -  Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and
             39, inclusive, is preferred

          -  Subject must meet the criteria of mildly or moderately impaired renal function or have
             normal renal function

          -  Subject with renal impairment must have evidence of stable disease

          -  If on medications for treatment of the complications of renal disease, and other
             concommitant chronic illnesses, subject must have been taking the medications at a
             stable dose for at least 10 days prior to the first Proellex® dosing date and are then
             to be continued at the same dose for the duration of the study.

          -  Negative urine pregnancy test at screening visit

          -  Subject must agree to use a medically acceptable and effective non-hormonal double
             barrier method of birth control

          -  Healthy subject must have no significant abnormal findings at the screening physical
             examination

          -  Subject is willing to remain in the clinic for the screening visit (approximately 1
             day for the first screening visit) and for the treatment visit (approximately 3 days)

          -  Additional inclusion criteria may apply

        Exclusion Criteria:

          -  Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant

          -  Subject with clinically significant abnormal liver function

          -  Pregnant or lactating females, or women who are attempting or expecting to become
             pregnant at any time during the study or one month after the study

          -  An acute illness within five (5) days of study medication administration

          -  Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or
             any other organ system

          -  Additional exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre van As, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2014</results_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 mg Proellex Mild Impairment</title>
          <description>50 mg Proellex single dose Female subjects with mild renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="P2">
          <title>50 mg Proellex Moderate</title>
          <description>50 mg Proellex, Female subjects with moderate renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="P3">
          <title>50 mg Proellex, Normal</title>
          <description>50 mg Proellex, Female subjects with normal renal function.
50 mg Proellex: Single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study prematurely terminated, no data available</population>
      <group_list>
        <group group_id="B1">
          <title>50 mg Proellex Mild Impairment</title>
          <description>50 mg Proellex single dose Female subjects with mild renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="B2">
          <title>50 mg Proellex Moderate</title>
          <description>50 mg Proellex, Female subjects with moderate renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="B3">
          <title>50 mg Proellex, Normal</title>
          <description>50 mg Proellex, Female subjects with normal renal function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Proellex</title>
        <time_frame>48 hours</time_frame>
        <population>Study prematurely terminated</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Proellex Mild Impairment</title>
            <description>50 mg Proellex single dose Female subjects with mild renal impairment function.
50 mg Proellex: Single dose</description>
          </group>
          <group group_id="O2">
            <title>50 mg Proellex Moderate</title>
            <description>50 mg Proellex, Female subjects with moderate renal impairment function.
50 mg Proellex: Single dose</description>
          </group>
          <group group_id="O3">
            <title>50 mg Proellex, Normal</title>
            <description>50 mg Proellex, Female subjects with normal renal function.
50 mg Proellex: Single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Proellex</title>
          <population>Study prematurely terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse event data is available</desc>
      <group_list>
        <group group_id="E1">
          <title>50 mg Proellex Mild Impairment</title>
          <description>50 mg Proellex single dose Female subjects with mild renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="E2">
          <title>50 mg Proellex Moderate</title>
          <description>50 mg Proellex, Female subjects with moderate renal impairment function.
50 mg Proellex: Single dose</description>
        </group>
        <group group_id="E3">
          <title>50 mg Proellex, Normal</title>
          <description>50 mg Proellex, Female subjects with normal renal function.
50 mg Proellex: Single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

